Search - tctmd.com

Displaying 401 - 420 of 441

Sort: Relevancy | Date

News Daily News

Los Afroamericanos Tienen Índices de Hemorragia Más Altos tras la Reperfusión de un STEMI

L.A. McKeown

March 20, 2012

News Daily News

La Definición Universal de IM se Posiciona en Favor del Cangrelor en las PCI

Caitlin E. Cox

March 20, 2012

News Daily News

Se Publica el TARGET-CABG: El Período de Espera al CABG depende de la Prueba de la Función Plaquetaria

Yael L. Maxwell

March 15, 2012

News Daily News

Relación Hemorragia Intrahospitalaria/Mortalidad tras Sufrir un NSTEMI

Caitlin E. Cox

March 12, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

Un Registro Confirma que en el ‘Mundo Real’ la Bivalirudina es Mejor contra el STEMI

March 07, 2012

News Daily News

Medidas Drásticas para Acortan el Tiempo de Derivación a una PCI Primaria

March 06, 2012

News Daily News

Análisis PLATO: Los IBP son Problemáticos tanto con el Ticagrelor como con el Clopidogrel

Caitlin E. Cox

March 06, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

News Daily News

New-Onset A-fib After Percutaneous Valve Repair More Common Than Thought

December 13, 2011

News Daily News

Hospital Readmission Post-PCI Linked to Increased Mortality

Yael L. Maxwell

December 05, 2011

News Conference News

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

Jason Kahn

November 30, 2011

News Conference News

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

November 13, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Industry News

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

November 08, 2011

News Conference News

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

November 08, 2011

News Industry News

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

November 08, 2011

News Industry News

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

November 08, 2011

Advertisement

Los Afroamericanos Tienen Índices de Hemorragia Más Altos tras la Reperfusión de un STEMI

La Definición Universal de IM se Posiciona en Favor del Cangrelor en las PCI

Se Publica el TARGET-CABG: El Período de Espera al CABG depende de la Prueba de la Función Plaquetaria

Relación Hemorragia Intrahospitalaria/Mortalidad tras Sufrir un NSTEMI

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

Un Registro Confirma que en el ‘Mundo Real’ la Bivalirudina es Mejor contra el STEMI

Medidas Drásticas para Acortan el Tiempo de Derivación a una PCI Primaria

Análisis PLATO: Los IBP son Problemáticos tanto con el Ticagrelor como con el Clopidogrel

SCAAR: Second-Generation DES Improve Hard Outcomes

New-Onset A-fib After Percutaneous Valve Repair More Common Than Thought

Hospital Readmission Post-PCI Linked to Increased Mortality

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

RAPID GENE: Validation of Point-of-Care Genetic Testing

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

Low CV Event Rate Prompts Closure of Prasugrel Trial

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content